Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Kenneth D. Cronin is active.

Publication


Featured researches published by Kenneth D. Cronin.


Hepatology | 2010

IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C.

Thomas J. Urban; Alexander J. Thompson; Shelton S. Bradrick; Jacques Fellay; Detlef Schuppan; Kenneth D. Cronin; Linda Hong; Alexander McKenzie; Keyur Patel; John G. McHutchison; David B. Goldstein; Nezam H. Afdhal

Genetic variation in the IL28B (interleukin 28B; interferon lambda 3) region has been associated with sustained virological response (SVR) rates in patients with chronic hepatitis C (CHC) who were treated with peginterferon‐α and ribavirin. We hypothesized that IL28B polymorphism is associated with intrahepatic expression of interferon‐stimulated genes (ISGs), known to influence treatment outcome. IL28B genotyping (rs12979860) and whole‐genome RNA expression were performed using liver biopsies from 61 North American patients with CHC. After correction for multiple testing (false discovery rate < 0.10), 164 transcripts were found to be differentially expressed by IL28B‐type. The interferon signaling pathway was the most enriched canonical pathway differentially expressed by IL28B‐type (P < 10−5), with most genes showing higher expression in livers of individuals carrying the poor‐response IL28B‐type. In 25 patients for which treatment response data were available, IL28B‐type was associated with SVR (P = 0.0054). ISG expression was also associated with SVR; however, this was not independent of IL28B‐type. Analysis of miR‐122 expression in liver biopsies showed reduced miR‐122 levels associated with poorer treatment outcome, independently of IL28B‐type. No association was observed between IL28B‐type and levels of liver IL28B or IL28A messenger RNA expression. IL28B protein sequence variants associated with rs12979860 were therefore investigated in vitro: no differences in ISG induction or inhibition of HCV replication were observed in Huh7.5 cells. Conclusion: The good response IL28B variant was strongly associated with lower level ISG expression. The results suggest that IL28B genotype may explain the relationship between hepatic ISG expression and HCV treatment outcome, and this is independent of miR‐122 expression. IL28B‐type was not associated with intrahepatic IL28B messenger RNA expression in vivo. Further investigation of the precise molecular mechanism(s) by which IL28B genetic variation influences HCV outcomes is warranted. (HEPATOLOGY 2010)


PLOS Biology | 2008

Tissue-Specific Genetic Control of Splicing: Implications for the Study of Complex Traits

Erin L. Heinzen; Dongliang Ge; Kenneth D. Cronin; Jessica M. Maia; Willow N Gabriel; Kathleen A. Welsh-Bohmer; Christine M. Hulette; Thomas N. Denny; David B. Goldstein

Numerous genome-wide screens for polymorphisms that influence gene expression have provided key insights into the genetic control of transcription. Despite this work, the relevance of specific polymorphisms to in vivo expression and splicing remains unclear. We carried out the first genome-wide screen, to our knowledge, for SNPs that associate with alternative splicing and gene expression in human primary cells, evaluating 93 autopsy-collected cortical brain tissue samples with no defined neuropsychiatric condition and 80 peripheral blood mononucleated cell samples collected from living healthy donors. We identified 23 high confidence associations with total expression and 80 with alternative splicing as reflected by expression levels of specific exons. Fewer than 50% of the implicated SNPs however show effects in both tissue types, reflecting strong evidence for distinct genetic control of splicing and expression in the two tissue types. The data generated here also suggest the possibility that splicing effects may be responsible for up to 13 out of 84 reported genome-wide significant associations with human traits. These results emphasize the importance of establishing a database of polymorphisms affecting splicing and expression in primary tissue types and suggest that splicing effects may be of more phenotypic significance than overall gene expression changes.


American Journal of Human Genetics | 2010

Rare deletions at 16p13.11 predispose to a diverse spectrum of sporadic epilepsy syndromes.

Erin L. Heinzen; Rodney A. Radtke; Thomas J. Urban; Gianpiero L. Cavalleri; Chantal Depondt; Anna C. Need; Nicole M. Walley; Paola Nicoletti; Dongliang Ge; Claudia B. Catarino; John S. Duncan; Dalia Kasperavičiūte; Sarah K. Tate; Luis O. Caboclo; Josemir W. Sander; Lisa M. Clayton; Kristen N. Linney; Curtis Gumbs; Jason Smith; Kenneth D. Cronin; Jessica M. Maia; Colin P. Doherty; Massimo Pandolfo; David Leppert; Lefkos T. Middleton; Rachel A. Gibson; Michael R. Johnson; Paul M. Matthews; David A. Hosford; Reetta Kälviäinen

Deletions at 16p13.11 are associated with schizophrenia, mental retardation, and most recently idiopathic generalized epilepsy. To evaluate the role of 16p13.11 deletions, as well as other structural variation, in epilepsy disorders, we used genome-wide screens to identify copy number variation in 3812 patients with a diverse spectrum of epilepsy syndromes and in 1299 neurologically-normal controls. Large deletions (> 100 kb) at 16p13.11 were observed in 23 patients, whereas no control had a deletion greater than 16 kb. Patients, even those with identically sized 16p13.11 deletions, presented with highly variable epilepsy phenotypes. For a subset of patients with a 16p13.11 deletion, we show a consistent reduction of expression for included genes, suggesting that haploinsufficiency might contribute to pathogenicity. We also investigated another possible mechanism of pathogenicity by using hybridization-based capture and next-generation sequencing of the homologous chromosome for ten 16p13.11-deletion patients to look for unmasked recessive mutations. Follow-up genotyping of suggestive polymorphisms failed to identify any convincing recessive-acting mutations in the homologous interval corresponding to the deletion. The observation that two of the 16p13.11 deletions were larger than 2 Mb in size led us to screen for other large deletions. We found 12 additional genomic regions harboring deletions > 2 Mb in epilepsy patients, and none in controls. Additional evaluation is needed to characterize the role of these exceedingly large, non-locus-specific deletions in epilepsy. Collectively, these data implicate 16p13.11 and possibly other large deletions as risk factors for a wide range of epilepsy disorders, and they appear to point toward haploinsufficiency as a contributor to the pathogenicity of deletions.


The Journal of Infectious Diseases | 2010

Host Determinants of HIV-1 Control in African Americans

Kimberly Pelak; David B. Goldstein; Nicole M. Walley; Jacques Fellay; Dongliang Ge; Curtis Gumbs; Xiaojiang Gao; Jessica M. Maia; Kenneth D. Cronin; Shehnaz K. Hussain; Mary Carrington; Nelson L. Michael; Amy C. Weintrob

We performed a whole-genome association study of human immunodeficiency virus type 1 (HIV-1) set point among a cohort of African Americans (n = 515), and an intronic single-nucleotide polymorphism (SNP) in the HLA-B gene showed one of the strongest associations. We use a subset of patients to demonstrate that this SNP reflects the effect of the HLA-B*5703 allele, which shows a genome-wide statistically significant association with viral load set point (P = 5.6 x 10(-10)). These analyses therefore confirm a member of the HLA-B*57 group of alleles as the most important common variant that influences viral load variation in African Americans, which is consistent with what has been observed for individuals of European ancestry, among whom the most important common variant is HLA-B*5701.


Human Molecular Genetics | 2009

Expansion of the Parkinson disease-associated SNCA-Rep1 allele upregulates human α-synuclein in transgenic mouse brain

Kenneth D. Cronin; Dongliang Ge; Paul Manninger; Colton Linnertz; Anna Rossoshek; Bonnie M. Orrison; David J. Bernard; Omar M. A. El-Agnaf; Michael G. Schlossmacher; Robert L. Nussbaum; Ornit Chiba-Falek

α-Synuclein (SNCA) gene has been implicated in the development of rare forms of familial Parkinson disease (PD). Recently, it was shown that an increase in SNCA copy numbers leads to elevated levels of wild-type SNCA-mRNA and protein and is sufficient to cause early-onset, familial PD. A critical question concerning the molecular pathogenesis of PD is what contributory role, if any, is played by the SNCA gene in sporadic PD. The expansion of SNCA-Rep1, an upstream, polymorphic microsatellite of the SNCA gene, is associated with elevated risk for sporadic PD. However, whether SNCA-Rep1 is the causal variant and the underlying mechanism with which its effect is mediated by remained elusive. We report here the effects of three distinct SNCA-Rep1 variants in the brains of 72 mice transgenic for the entire human SNCA locus. Human SNCA-mRNA and protein levels were increased 1.7- and 1.25-fold, respectively, in homozygotes for the expanded, PD risk-conferring allele compared with homozygotes for the shorter, protective allele. When adjusting for the total SNCA-protein concentration (endogenous mouse and transgenic human) expressed in each brain, the expanded risk allele contributed 2.6-fold more to the SNCA steady-state than the shorter allele. Furthermore, targeted deletion of Rep1 resulted in the lowest human SNCA-mRNA and protein concentrations in murine brain. In contrast, the Rep1 effect was not observed in blood lysates from the same mice. These results demonstrate that Rep1 regulates human SNCA expression by enhancing its transcription in the adult nervous system and suggest that homozygosity for the expanded Rep1 allele may mimic locus multiplication, thereby elevating PD risk.


PLOS ONE | 2009

Genetic Regulation of α-Synuclein mRNA Expression in Various Human Brain Tissues

Colton Linnertz; Laura Saucier; Dongliang Ge; Kenneth D. Cronin; James R. Burke; Jeffrey N. Browndyke; Christine M. Hulette; Kathleen A. Welsh-Bohmer; Ornit Chiba-Falek

Genetic variability across the SNCA locus has been repeatedly associated with susceptibility to sporadic Parkinsons disease (PD). Accumulated evidence emphasizes the importance of SNCA dosage and expression levels in PD pathogenesis. However whether genetic variability in the SNCA gene modulates the risk to develop sporadic PD via regulation of SNCA expression remained elusive. We studied the effect of PD risk-associated variants at SNCA 5′ and 3′regions on SNCA-mRNA levels in vivo in 228 human brain samples from three structures differentially vulnerable to PD pathology (substantia-nigra, temporal- and frontal-cortex) obtained from 144 neurologically normal cadavers. The extensively characterized PD-associated promoter polymorphism, Rep1, had an effect on SNCA-mRNA levels. Homozygous genotype of the ‘protective’, Rep1-259 bp allele, was associated with lower levels of SNCA-mRNA relative to individuals that carried at least one copy of the PD-risk associated alleles, amounting to an average decrease of ∼40% and >50% in temporal-cortex and substantia-nigra, respectively. Furthermore, SNPs tagging the SNCA 3′-untranslated-region also showed effects on SNCA-mRNA levels in both the temporal-cortex and the substantia-nigra, although, in contrast to Rep1, the ‘decreased-risk’ alleles were correlated with increased SNCA-mRNA levels. Similar to Rep1 findings, no difference in SNCA-mRNA level was seen with different SNCA 3′SNP alleles in the frontal-cortex, indicating there is brain-region specificity of the genetic regulation of SNCA expression. We provide evidence for functional consequences of PD-associated SNCA gene variants in disease relevant brain tissues, suggesting that genetic regulation of SNCA expression plays an important role in the development of the disease.


Journal of Neuropathology and Experimental Neurology | 2007

Postmortem Delay Has Minimal Effect on Brain RNA Integrity

John F. Ervin; Erin L. Heinzen; Kenneth D. Cronin; David B. Goldstein; Mari Szymanski; James R. Burke; Kathleen A. Welsh-Bohmer; Christine M. Hulette

The Bryan Alzheimer Disease Research Center obtains postmortem human brain tissue from patients with Alzheimer disease (AD) and cognitively normal control subjects for molecular and genetic research programs. A growing body of research suggests that variations in gene transcript levels may contribute to the onset and progression of disease. Identifying how the regulation of gene expression may affect AD requires the use of high-quality mRNA from banked human brains. The present study was conducted to establish the quality and suitability of available banked brain tissue for future gene expression studies. We chose 32 AD cases with Braak stage IV, V, or VI. These AD cases were matched to 36 normal control cases by age and sex when possible. Multiple regions from each brain were sampled, including frontal cortex, temporal cortex, occipital cortex, and cerebellum. Hippocampus was also available for study from 14 control cases. A comparison of several antemortem and postmortem variables, such as postmortem interval, agonal state, ventricular cerebrospinal fluid pH, and cause of death were analyzed. RNA was isolated from at least 1 area from every brain and most brains yielded intact RNA from all regions tested. Analysis of the clinical variables did not reveal any features that correlated with the ability to recover intact mRNA. We conclude that undegraded mRNA may be isolated from most brain regions many hours postmortem and that neither the pH of ventricular fluid nor postmortem interval is predictive of mRNA integrity.


Clinical Genetics | 2015

The RBMX gene as a candidate for the Shashi X-linked intellectual disability syndrome.

Vandana Shashi; Pingxing Xie; Kelly Schoch; David B. Goldstein; Timothy D. Howard; Margaret N. Berry; C.E. Schwartz; Kenneth D. Cronin; S. Sliwa; Andrew S. Allen; Anna C. Need

A novel X‐linked intellectual disability (XLID) syndrome with moderate intellectual disability and distinguishing craniofacial dysmorphisms had been previously mapped to the Xq26‐q27 interval. On whole exome sequencing in the large family originally reported with this disorder, we identified a 23 bp frameshift deletion in the RNA binding motif protein X‐linked (RBMX) gene at Xq26 in the affected males (n = 7), one carrier female, absent in unaffected males (n = 2) and in control databases (7800 exomes). The RBMX gene has not been previously causal of human disease. We examined the genic intolerance scores for the coding regions and the non‐coding regions of RBMX; the findings were indicative of RBMX being relatively intolerant to loss of function variants, a distinctive pattern seen in a subset of XLID genes. Prior expression and animal modeling studies indicate that loss of function of RBMX results in abnormal brain development. Our finding putatively adds a novel gene to the loci associated with XLID and may enable the identification of other individuals affected with this distinctive syndrome.


Epilepsia | 2016

Differential gene expression in dentate granule cells in mesial temporal lobe epilepsy with and without hippocampal sclerosis

Nicole G. Griffin; Yu Wang; Christine M. Hulette; Matt Halvorsen; Kenneth D. Cronin; Nicole M. Walley; Michael M. Haglund; Rodney A. Radtke; J. H. Pate Skene; Saurabh R. Sinha; Erin L. Heinzen

Hippocampal sclerosis is the most common neuropathologic finding in cases of medically intractable mesial temporal lobe epilepsy. In this study, we analyzed the gene expression profiles of dentate granule cells of patients with mesial temporal lobe epilepsy with and without hippocampal sclerosis to show that next‐generation sequencing methods can produce interpretable genomic data from RNA collected from small homogenous cell populations, and to shed light on the transcriptional changes associated with hippocampal sclerosis.


Cold Spring Harb Mol Case Stud | 2017

Uniparental disomy of Chromosome 16p in hemimegalencephaly

Nicole G. Griffin; Kenneth D. Cronin; Nicole M. Walley; Christine M. Hulette; Gerald A. Grant; Mohamad A. Mikati; Heather G. LaBreche; Catherine Rehder; Andrew S. Allen; Peter B. Crino; Erin L. Heinzen

Hemimegalencephaly (HME) is a heterogeneous cortical malformation characterized by enlargement of one cerebral hemisphere. Somatic variants in mammalian target of rapamycin (mTOR) regulatory genes have been implicated in some HME cases; however, ∼70% have no identified genetic etiology. Here, we screened two HME patients to identify disease-causing somatic variants. DNA from leukocytes, buccal swabs, and surgically resected brain tissue from two HME patients were screened for somatic variants using genome-wide genotyping arrays or sequencing of the protein-coding regions of the genome. Functional studies were performed to evaluate the molecular consequences of candidate disease-causing variants. Both HME patients evaluated were found to have likely disease-causing variants in DNA extracted from brain tissue but not in buccal swab or leukocyte DNA, consistent with a somatic mutational mechanism. In the first case, a previously identified disease-causing somatic single nucleotide in MTOR was identified. In the second case, we detected an overrepresentation of the alleles inherited from the mother on Chromosome 16 in brain tissue DNA only, indicative of somatic uniparental disomy (UPD) of the p-arm of Chromosome 16. Using methylation analyses, an imprinted locus on 16p spanning ZNF597 was identified, which results in increased expression of ZNF597 mRNA and protein in the brain tissue of the second case. Enhanced mTOR signaling was observed in tissue specimens from both patients. We speculate that overexpression of maternally expressed ZNF597 led to aberrant hemispheric development in the patient with somatic UPD of Chromosome 16p possibly through modulation of mTOR signaling.

Collaboration


Dive into the Kenneth D. Cronin's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Erin L. Heinzen

Columbia University Medical Center

View shared research outputs
Top Co-Authors

Avatar

David B. Goldstein

Columbia University Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Curtis Gumbs

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Anna C. Need

Imperial College London

View shared research outputs
Researchain Logo
Decentralizing Knowledge